MaxCyte, Inc. Notice of Full Year Results (9554T)
26 March 2019 - 6:01PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9554T
MaxCyte, Inc.
26 March 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Full Year Results
Gaithersburg, Maryland - 26 March 2019: MaxCyte (LSE: MXCT,
MXCS), the global cell-based medicines and life sciences company,
will be announcing its full year audited results for the year ended
31 December 2018 on Wednesday, 24 April 2019.
Doug Doerfler, Chief Executive Officer, will host a presentation
and live conference call and webcast for analysts at 11.00am BST on
the day of the results at the offices of Panmure Gordon, One New
Change, London, EC4M 9AF.
During the presentation the Company is expected to confirm
strong financial progress over the 2018 period, as outlined in the
recent trading update; to provide an overview of the Company's
novel and proprietary CARMA cell therapy platform in
immuno-oncology and the clinical study, which is now underway, of
its first wholly-owned lead CAR therapeutic candidate, MCY-M11;
and, to highlight key commercial-stage license agreements with
leading biotech companies including Kite Pharma, CRISPR
Therapeutics and Precision BioSciences.
About MaxCyte
MaxCyte is a clinical-stage global cell-based medicines and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA(TM)
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation(R) Technology to enable
its biopharmaceutical partners to advance the development of
innovative medicines, particularly in cell therapy. MaxCyte has
placed its flow electroporation instruments worldwide, with all of
the top ten global biopharmaceutical companies. The Company now has
more than 70 partnered program licenses in cell therapy with more
than 35 licensed for clinical use, including four announced
commercial licenses covering potentially more than 30 products with
aggregate potential milestones of more than $250M. With its robust
delivery technology platform, MaxCyte helps its partners to unlock
the full potential of their products. For more information, visit
www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORJAMTTMBJTTBL
(END) Dow Jones Newswires
March 26, 2019 03:01 ET (07:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024